Acute Respiratory Illnesses in Children in the SARS-CoV-2 Pandemic: Prospective Multicenter Study


DOI: 10.1542/peds.2021-051462
Journal: Pediatrics
Article Type: Regular Article

This is a prepublication version of an article that has undergone peer review and been accepted for publication but is not the final version of record. This paper may be cited using the DOI and date of access. This paper may contain information that has errors in facts, figures, and statements, and will be corrected in the final published version. The journal is providing an early version of this article to expedite access to this information. The American Academy of Pediatrics, the editors, and authors are not responsible for inaccurate information and data described in this version.
Acute Respiratory Illnesses in Children in the SARS-CoV-2 Pandemic: Prospective Multicenter Study

Zaid Haddadin, MD\(^1\), Jennifer E. Schuster, MD, MSCI\(^2\), Andrew J. Spieker, PhD\(^3\), Herdi Rahman, BS\(^1\), Anna Blozinski, MPH\(^1\), Laura Stewart, PhD\(^4\), Angela P. Campbell, MD MPH\(^4\), Joana Y. Lively, MPH\(^4\)-\(^5\), Marian G. Michaels, MD, MPH\(^6\), John V. Williams, MD\(^6\), Julie A. Boom, MD\(^7\)-\(^8\), Leila C. Sahni, PhD, MPH\(^7\)-\(^8\), Mary Staat, MD, MPH\(^9\), Monica McNeal, PhD\(^9\), Rangaraj Selvarangan, PhD\(^2\)-\(^10\), Christopher J. Harrison, MD\(^2\), Geoffrey A. Weinberg, MD\(^11\), Peter G. Szilagyi, MD, MPH\(^11\)-\(^12\), Janet A. Englund, MD\(^11\), Eileen J. Klein, MD, MPH\(^13\), Aaron T. Curns, MPH\(^4\), Brian Rha, MD, MSPH\(^4\), Gayle E. Langley MD, MPH\(^4\), Aron J. Hall, DVM, MSPH\(^4\), Manish M. Patel, MD, MPH\(^4\), Natasha B. Halasa, MD, MPH\(^1\)

\(^1\)Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN
\(^2\)Division of Pediatric Infectious Diseases, University of Missouri – Kansas City, Children's Mercy Hospital, Kansas City, MO
\(^3\)Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN
\(^4\)Centers for Disease Control and Prevention COVID-19 Response Team, Atlanta, GA
\(^5\)IHRC, Inc., Atlanta, GA
\(^6\)Department of Pediatrics, University of Pittsburgh School of Medicine, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA
\(^7\)Department of Pediatrics, Baylor College of Medicine, Houston, TX
\(^8\)Texas Children's Hospital, Houston, TX
\(^9\)Department of Pediatrics, University of Cincinnati College of Medicine, Division of Infectious Diseases, Cincinnati Children’s Hospital, Cincinnati, OH
\(^10\)Department of Pathology and Laboratory Medicine, University of Missouri – Kansas City, Children's Mercy Hospital, Kansas City, MO
\(^11\)Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, NY
\(^12\)Department of Pediatrics, UCLA Mattel Children's Hospital, University of California at Los Angeles, Los Angeles, CA
\(^13\)Department of Pediatrics, Seattle Children’s Hospital, Seattle, WA

Primary Corresponding author:

Natasha Halasa, MD, MPH

Vanderbilt University Medical Center; Division of Pediatric Infectious Diseases; 1161 21st Ave South, Medical Center North D7232; Nashville, TN 37232
Phone number: (615) 322-3346
Fax number: (615) 343-9723
Email: Natasha.halasa@vumc.org

Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
**Funding:** This work was supported by the US Centers for Disease Control and Prevention (cooperative agreement number CDC-RFA-IP16-004) and UL1 TR000445 from NCATS/NIH.

**Role of Funder/Sponsor:** The CDC provided funding for subjects enrollment, sample collection and testing, and also participated in the design of the study. NIH grant to support REDCap.

**Conflicts of Interest**
Jennifer E. Schuster receives support from Merck. John V. Williams is on boards for Quidel and GSK. JenChristopher Harrison’s institution receives support from GlaxoSmithKline, Merck, and Pfizer. Janet Englund is a consultant for Sanofi Pasteur, Meissa Vaccines, and institutional research support from AstraZeneca, GlaxoSmithKline, Pfizer, and Novavax. Natasha Halasa has grant funding from Sanofi, Quidel, and received an honorarium from an educational grant from Genentech. All other authors: No reported conflicts of interest.

**Abbreviations:** ARI: acute respiratory illnesses; RSV: respiratory syncytial virus; ED: emergency department; US: united states; SARS-CoV-2: severe acute respiratory syndrome; COVID-19: coronavirus 2 the cause of coronavirus disease 2019; CDC: centers for disease control and prevention; ILI: influenza-like illnesses.

**Table of Contents Summary**
This prospective, multicenter, surveillance study evaluates the frequency of ARI in children before and during the COVID-19 pandemic within seven cities in the United States.

**What’s Known on This Subject**
While decreases in ARI during the COVID-19 community mitigation periods have been described, it is unknown whether such strategies have decreased severe cases of ARI requiring management in emergency departments and inpatient settings across different cities in the United States.

**What This Study Adds**
In over 25,000 prospectively enrolled children from seven geographically diverse United States cities, this study showed fewer ARI cases and lower odds of testing positive for RSV and influenza, during the COVID-19 mitigation period compared to 2016-2019.
Contributors’ Statement Page

Dr. Haddadin, conceptualized and designed the study, performed the initial analyses, drafted the initial manuscript, and reviewed and revised the manuscript.

Drs. Schuster, Stewart, Campbell, Michaels, Williams, Boom, Sahni, Staat, McNeal, Selvarangan, Harrison, Weinberg, Szilagyi, Englund, Klein, Rha, Langley, Patel and Halasa and Ms. Lively conceptualized and designed the study, designed the data collection instruments, coordinated and supervised data collection and testing, and reviewed and revised the manuscript.

Mr. Rahman, Ms. Blozinski and Dr. Andrew Spieker performed and supervised data analysis, and reviewed and revised the manuscript.

Mr. Curns contributed significantly to acquisition of data, and revised the manuscript critically for important intellectual content.

Dr. Hall contributed significantly to conception and design of the study, interpretation of data and revised the manuscript critically for important intellectual content.

All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.
Abstract

Objectives

Non-pharmaceutical interventions against COVID-19 likely have a role in decreasing viral acute respiratory illnesses (ARI). This study aimed to assess the frequency of respiratory syncytial virus (RSV) and influenza ARI in children, before and during the COVID-19 pandemic.

Methods

This study was a prospective, multicenter, population-based ARI surveillance, including children <18 years presenting with fever and/or respiratory symptoms to emergency departments (ED) and inpatient settings in seven United States (US) cities. Respiratory samples were collected and evaluated by molecular testing. Data were analyzed by calendar weeks. Generalized linear mixed-effects models were used to evaluate the association between community mitigation and number of eligible cases, and proportion testing positive for RSV and influenza.

Results

Overall, 45,759 children were eligible; 25,415 were enrolled and tested; 25% were RSV-positive, and 14% were influenza-positive. In 2020, we noted a decrease in eligible and enrolled ARI subjects after community mitigation measures were introduced, with no RSV or influenza detection in 4/5-4/30/2020. Compared to 2016-2019, there was an average of 10.6 fewer eligible ARI cases/week per site and 63.9% and 45.8% lower odds of testing positive for RSV and influenza, respectively, during the 2020 community mitigation period. In all sites except Seattle, the proportions of positive RSV and influenza in the 2020 community mitigation period were lower than predicted.

Conclusion

In March-April 2020, rapid declines in ARI cases and the proportions of RSV and influenza in children were consistently noted across seven US cities, which could be attributable to community mitigation measures against SARS-CoV-2.

Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), is a highly contagious respiratory virus, primarily transmitted between humans through exposure to respiratory droplets and aerosols from infected individuals.1 Early in the pandemic, national and global efforts have focused on community mitigation strategies to prevent the spread of SARS-CoV-2 throughout the pandemic in the absence of available vaccines and medical interventions. Community mitigation strategies have
included hand hygiene, use of face coverings, social distancing, and limiting mass gatherings. Moreover, many school closures and stay-at-home orders were widely implemented in the United States (US) by early spring 2020.

Previous studies have demonstrated decreased transmission, infection, and mortality during influenza pandemics when similar community mitigation measures were implemented in a timely, appropriate, and sustainable manner. Recent evidence reflects the importance of community mitigation strategies in decreasing COVID-19 cases. Several studies during the pandemic have demonstrated a decline in medically attended acute respiratory illnesses (ARI) and decreased activity of seasonal respiratory viruses, including influenza. Restrictions among available healthcare resources have also altered practice patterns (such as increased use of telemedicine) and clinical and research priorities to slow SARS-CoV-2 spread and alleviate stress on the healthcare system. In addition, a decline in child vaccination coverage suggests that patients have been reluctant to procure healthcare during the pandemic. These healthcare practices and behavioral changes might result in overall declines in medically attended ARI, especially milder cases that could be managed at home.

However, it is unknown whether such community mitigation strategies have decreased severe cases of ARIs that would require management in emergency department (ED) and inpatient settings. For example, respiratory syncytial virus (RSV) and influenza are among the most common causes of ARI in children, both associated with increased disease severity, and generally peak in winter and early-spring months each year. Therefore, this study aimed to (1) assess the frequency of ARI in children, including those due to RSV and influenza, in both
the ED and inpatient settings, before and during the pandemic within a US multicenter active surveillance network, and (2) whether the proportions of such ARIs testing positive for RSV and influenza during the COVID-19 mitigation period in 2020 were lower than in prior seasons.

Methods

Study Design

Provisional data were obtained from the New Vaccine Surveillance Network (NVSN), a prospective, population-based ARI surveillance platform funded by the Centers for Disease Control and Prevention (CDC). Surveillance for ARI in NVSN was reestablished in 2015 and the current seven US pediatric medical centers are located in: Cincinnati, OH; Houston, TX; Kansas City, MO; Nashville, TN; Pittsburgh, PA; Rochester, NY; and Seattle, WA. Subject recruitment occurred ≥4 days/week in the emergency department (ED) and ≥5 days/week in inpatient settings over four respiratory seasons. Analyses were restricted to subjects recruited during December 2016 to April 2017, and October to April each year from 2017 to 2020. The CDC’s and each institution’s Institutional Review Boards approved the study.

Study Population

Children under 18 years were eligible for enrollment if they resided within a site’s surveillance area and visited the ED or were admitted to the hospital within 48 hours of enrollment with ≥1 of the following symptoms: fever, cough, earache, nasal congestion, runny nose, sore throat, post-tussive vomiting, wheezing, shortness of breath/rapid or shallow breathing, apnea, apparent life-threatening event, brief resolved unexplained event, or myalgias; and duration of illness <14 days. Children were excluded if they had a known non-respiratory cause for their illness,
chemotherapy-associated fever and neutropenia, been transferred from another hospital after an admission of >48 hours, were admitted <5 days after a previous hospitalization, were never discharged home after birth, or had previous enrollment in the study <14 days before current enrollment. Of note, three sites restricted ED enrollment primarily to children under five years during most of the periods of interest (Seattle during December 2016–April 2017, November 2017–April 2018, November 2018–April 2019, and December 2019–March 2020; Pittsburgh during December 2016–April 2018, November 2018–April 2019, and December 2019–March 2020; Kansas City during December 2016–April 2017, November 2017–April 2018, November 2018–April 2019).

**Data and Specimen Collection**

After obtaining informed consent, the research staff interviewed the child’s parent and/or guardian using a standardized case report form that included demographic information (including age, race and ethnicity). Mid-turbinate nasal swabs and oropharyngeal swabs were collected and combined in viral transport media by study personnel or clinical staff from enrolled children. For intubated patients, tracheal aspirates were accepted as alternatives to oropharyngeal swabs. When nasal, oropharyngeal, or tracheal aspirate specimens were not available, clinically salvaged respiratory specimens were obtained. Specimens were transported to each site laboratory and stored at 2°C to 8°C until processed (within 72 hours). Specimens underwent testing at each site by commercial or institution-specific in-house reverse transcription-polymerase chain reaction assays for RSV and influenza. Diagnostic assay methods varied by site and included Luminex NxTAG Respiratory Pathogen Panel (Cincinnati and Kansas City), BioFire FilmArray Respiratory Panel (Seattle), Applied Biosystems TaqMan Array Microfluidic
Card (Rochester), and in-house real-time reverse transcription-polymerase chain reaction assays (Houston, Pittsburgh, and Nashville).\textsuperscript{18} All sites conducted CDC-sponsored proficiency testing to ensure the validity and consistency of respiratory viral detections at each site.\textsuperscript{18, 19}

**COVID-19 Pandemic-related Restrictions and Community Mitigation Dates**

Research enrollment activities were paused or limited for several weeks in March at all sites as institutional policies suspended clinical research to conserve supplies and personal protective equipment during the COVID-19 pandemic. Enrollment occurred at a single children’s hospital at six sites and at two children’s hospitals in Rochester; capacity to care for children was not affected in any of these hospitals during the pandemic. \textbf{Table 1} shows the dates of suspension of enrollment, school-closures, and stay-at-home order implementation by study site, which were provided by principal investigators, as instituted by local orders at each site. The total number of daily eligible and enrolled children in the ED and inpatient settings during the study period were provided by all sites. Community mitigation onset was defined as the earliest of either school closures or stay-at-home orders. The community mitigation period was defined as the first full calendar week following community mitigation initiation (\textbf{Table 1}) until the end of the study period (i.e., April 30, 2020 for all sites).

**Statistical Analysis**

Descriptive statistics were summarized as frequency (percentage) for categorical variables or median (interquartile range) for continuous variables. The number of eligible and enrolled children and proportions of RSV and influenza were evaluated by calendar weeks each season.
Children who were originally enrolled in the ED but then admitted, we classified their final status as the inpatient setting.

We sought to evaluate whether eligible case numbers and proportions testing positive for RSV and influenza were lower during the COVID-19 pandemic-related community mitigation period as compared to “baseline”. Baseline was defined as the same calendar weeks during 2016-2019. We fit generalized linear mixed-effects models (linear to model the mean number of eligible cases to obtain mean differences, and binomial-logit to model the odds of testing positive for RSV and influenza, separately, among enrolled cases). We included random effects for study site and season and fixed effects for categorical calendar week in each model, further including for each model the two prior weeks of corresponding outcomes (i.e., lagged outcomes) as covariates (flu and RSV cases are understood to be heavily driven by cases occurring in recent weeks).

We also aimed to evaluate whether eligible case numbers and proportions testing positive for RSV and influenza during the COVID-19 pandemic-related community mitigation period were as would have been predicted based on data from previous years. Regression models for eligible cases (linear) and proportions testing positive for RSV and influenza (logistic) were based on data from all sites prior to mitigation. Each model included two weeks of lagged outcomes, a two-way interaction between study site and season alone with each lower-order term, and a restricted cubic spline on calendar week with six knots positioned at equally-spaced quantiles. The fitted regression models were then used to generate predicted means/proportions for the community mitigation period, which were graphically represented in conjunction with pre-mitigation predictions using a locally weighted scatterplot smoother (LOWESS). We used a
nominal significance level of 0.05 (two-tailed) for all analyses. All statistical analyses were performed using StataCorp, College Station, TX software (version 15.1), and R version 4.0.2.

**Results**

Over four respiratory seasons from 2016–2020, 45,759 eligible children with ARI were identified: 27,114 (59%) from the ED, and 18,645 (41%) from the inpatient setting. Overall, 25,415 (56%) were enrolled and had respiratory specimens collected and tested for RSV and/or influenza. The cohort median age was 19 months (interquartile range 7–50), with 56% male and 33% non-Hispanic White. Overall, 25% of the samples were RSV-positive, and 14% were influenza-positive. A total of 12,366 subjects were enrolled from ED and then discharged to home; 18% and 19% were RSV and influenza positive, respectively. A total of 13,049 were enrolled and their final status was the inpatient setting; 32% and 8% were RSV and influenza-positive, respectively.

The number of eligible and enrolled subjects and the proportions of RSV and influenza by calendar week stratified by season are shown in **Figure 1**. In 2020, each study site had an estimated average of 10.6 (95% CI: [5.92, 15.2]; p < 0.001) fewer eligible ARI cases per calendar week per site during the community mitigation period as compared to the corresponding periods in previous years.

The cumulative proportions of weekly RSV and influenza detections by study season are shown in greater detail in **Figure 2**. Compared to previous seasons, RSV and influenza detections in 2020 stopped after week 15. In 2020, no RSV or influenza detections were observed in weeks
15–18 (4/5–4/30) in either the ED or inpatient settings (Figure 3). Among enrolled cases, the odds of testing positive for RSV was estimated to be 63.9% (95% CI: [23.5%, 82.9%]; p = 0.008) lower in the community mitigation period of 2020 as compared to the corresponding time periods in previous years; for influenza, the odds were 45.8% (95% CI: [7.64%, 68.2%]; p = 0.024) lower.

Regression models were developed for all seven sites by study year for total eligible (Figure 4A), proportion positive for RSV (Figure 4B), and proportion positive for influenza (Figure 4C). Based on fitted lines by season, for all sites except Seattle, the number of eligible ARI cases and proportion positive for RSV and influenza among those enrolled in the 2020 community mitigation period was lower than what would have been predicted based on data from site- and time-adjusted trajectories that were present pre-mitigation (Figures 4A, B, C).

Discussion
This prospective multicenter population-based ARI surveillance study found a substantial and sustained decline in medically attended ARI visits and the proportion of enrolled children with RSV or influenza infection in seven distinct geographic cities in the United States. These declines occurred promptly after community mitigation measures were implemented at each site in response to the pandemic.

Published studies have documented that these measures effectively decreased the reported burden of COVID-19 cases, with a robust temporal association between the timing of these strategies and the decrease in the trend in the epidemic growth rate of reported COVID-19 cases.4, 5, 20 The majority of community mitigation strategies in each of the seven study sites were
implemented around mid-March 2020; following these dates, we noted significantly fewer
estimated eligible cases and lower odds of RSV and influenza-positive children compared to the
same periods in previous seasons. A reduction in eligible case numbers during community
mitigation periods can be explained in part by several other factors, including changes in
healthcare-seeking behaviors, and limited access to medical care. However, it is less
plausible that such factors explain the reduction in the proportions of positive detections of RSV
and influenza among enrolled subjects, or in the frequency of cases of severe ARIs that are
hospitalized. Our study results are consistent with the hypothesis that community mitigation can
slow the spread of severe RSV and influenza infections, similar to the experiences with SARS-
CoV-2.

We found that the proportion of influenza-positive cases in the ED or inpatient setting in 2020
community mitigation period is lower than what would have been predicted at most site
locations, except Seattle. However, there were no cases of influenza detected in Seattle after
week 15, consistent with the other sites. Similar non-medical interventions were found effective
in prior influenza pandemics, including the 1918–1919 influenza pandemic, when medical
interventions were unavailable, and in more recent severe epidemics, when they were used
together with medical interventions. A surveillance study that monitored influenza-like
illnesses (ILI) and laboratory-confirmed influenza in New York showed that ILI decreased with
an average decrease of 96.9–98.9% in daily laboratory-confirmed influenza case rate/100,000 in
different regions in New York during the COVID-19 pandemic. Similarly, Sakamoto et al.
evaluated the effects of social isolation and adherence to personal hygiene on influenza weekly
activity in all age groups in Japan. Compared to the same periods in preceding years in their
study, influenza activity was significantly lower in January–March 2020, coinciding with mitigation efforts. Young et al. evaluated the 2019–2020 influenza season compared to previous years, and noted steeper declines in new influenza cases following the seasonal influenza peak in China and in Italy, which coincided with a substantial increase in COVID-19 cases in these countries. While the mainstay for preventing influenza remains annual vaccination, our findings suggest that in future severe influenza pandemics, similar community mitigation measures might reduce the incidence of severe influenza infection in children.

This study compared the proportion of RSV-infected children detected before and after social isolation measures in seven cities in the United States. RSV is a major cause of ARI hospitalizations in young children during the fall and winter months and associated with significant morbidity. We found a greater than 70% decrease in RSV-positive ARI in the community mitigation period in 2020 compared to the same period in prior surveillance seasons during which similar enrollment protocols were used. Baker et al. used laboratory surveillance data from 2020 and estimated that RSV transmission declined by at least 20% in the United States. Further active surveillance is needed during community mitigation periods to understand if RSV circulation in the United States can be affected by these measures.

Several reports indicated that parents were reluctant to take their children to healthcare facilities during this pandemic due to fear of SARS-CoV-2 exposure, which could in part contribute to the decline in the number of eligible subjects with ARI. However, we assume that the main effects would be on mild ARI that could be managed outside of the inpatient settings. Although the number of eligible hospitalized ARI subjects decreased in our study during the period of
COVID-19 mitigation, healthcare-seeking behavior was less likely to be responsible if we assume presentation of severely ill children would not have been demonstrably altered during this period. Further, local healthcare providers and researchers altered their practices and priorities during the early part of the COVID-19 pandemic, which posed limitations in our enrollment. Nonetheless, all sites recorded the number of eligible subjects even when enrollment was not possible due to institution-specific mandates in research curtailment. These data showed a significant decrease in the number of eligible subjects in 2020, as well as in the proportions positive for RSV and influenza. Additionally, a sensitivity analysis only including the three sites with no pauses in enrollments showed significant decreases for eligible and RSV cases, and similar point estimates for influenza cases, albeit not significant, which may be explained by insufficient power given the reduction in sample size. It might be expected, if confounding by limitations of enrollment to only the most ill children was influential, that the proportions of enrolled children with RSV and influenza detection might have increased, not decreased, especially since RSV and influenza are important causes of severe ARI in children.

Both RSV and influenza activity show natural fluctuations from season to season such that the decrease in RSV and influenza detections in our study might be partially explained by seasonal variation or even differences in virulence of circulating viral strains. The use of four seasons of data from the same study sites using similar enrollment criteria across wide geographic settings makes secular seasonal and virulence trends less likely to explain our findings of abrupt curtailment of RSV and influenza circulation among children in the study sites. We likewise accounted for between-site and between-year variations in prospective...
surveillance data. Also, we focused on comparing outcomes from the community mitigation period to comparable periods from previous years, and by including lag variables from two weeks leading up to the community mitigation period to reduce the confounding effects of a hiatus in enrollment as the mitigation period began. The major strengths of our study included the use of sensitive, validated molecular virologic testing, analysis of a large sample size from seven geographically diverse cities across the United States, and the use of consistent enrollment procedures over four years of active, prospective, ARI surveillance.

In summary, after COVID-19 community mitigation procedures were implemented, we noted a consistently sharp decline in children with ARI seeking medical care in EDs or being admitted to hospitals at our study institutions across seven US cities early in the pandemic. Furthermore, there were no RSV or influenza cases reported approximately 2–4 weeks after these measures were implemented in weeks 11–13, which contrasted with predictions based on data from prior seasons when mitigation measures were not in effect. This study validates the importance of ongoing active ARI surveillance in children to determine trends in viral positivity before, during, and after interventions, including implementation of community mitigation strategies during public health emergencies and pandemics. Future studies are needed to confirm our findings, especially in the upcoming RSV and influenza respiratory season, as our data suggest that community mitigation measures may have contributed to decreased RSV and influenza disease activity in young children.

Acknowledgments
We thank the children and parents who participated in this study.
References


Table 1. Dates of Community Mitigation Measures Implementation and Enrollment Suspension Periods, by Study Site.*

<table>
<thead>
<tr>
<th>Site</th>
<th>School-closure</th>
<th>Stay-at-home orders</th>
<th>IP suspension of enrollment dates</th>
<th>ED suspension of enrollment dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nashville, TN</td>
<td>3/16/2020</td>
<td>3/23/2020</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Rochester, NY**</td>
<td>3/13/2020</td>
<td>3/13/2020</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Seattle, WA</td>
<td>3/17/2020</td>
<td>3/23/2020</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

IP: inpatient; ED: emergency department

* Community mitigation onset was defined as the earliest of either school closures or stay-at-home orders. The community mitigation period was defined as the first full calendar week following community mitigation initiation until the end of the study period (i.e., April 30, 2020 for all sites).

**Enrollment was ceased from 3/16/2020 to 3/24/2020 in IP and ED settings in one affiliated hospital in the participating network.
**Figure 1.** Numbers of Eligible and Enrolled Acute Respiratory Illness Cases, and Proportions of Respiratory Syncytial Virus (RSV) and Influenza Detection by Week, Stratified by Study Season.
Figure 2. Cumulative Proportions of Weekly Respiratory Syncytial Virus (RSV) and Influenza Detection by Study Season.
Figure 3. Number of Cases of Respiratory Syncytial Virus (RSV) and Influenza Detection by Week Over the Four-Year Study Period, Stratified by Clinical Setting.
Figure 4. Graphic Representation of Predicted Mean A. Eligible Cases and Proportions of B. Respiratory Syncytial Virus (RSV) and C. Influenza Positive Enrolled Cases for the Community Mitigation Period, in Conjunction with Pre-Mitigation Predictions Using A LOWESS Smoother. (*please see Table 1 for specific halting of enrollments at each specific site).
### Figure 4.B. Proportion Testing Positive for RSV

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Nashville</td>
<td><img src="image1" alt="Graph" /></td>
<td><img src="image2" alt="Graph" /></td>
<td><img src="image3" alt="Graph" /></td>
<td><img src="image4" alt="Graph" /></td>
</tr>
<tr>
<td>Rochester</td>
<td><img src="image5" alt="Graph" /></td>
<td><img src="image6" alt="Graph" /></td>
<td><img src="image7" alt="Graph" /></td>
<td><img src="image8" alt="Graph" /></td>
</tr>
<tr>
<td>Cincinnati</td>
<td><img src="image9" alt="Graph" /></td>
<td><img src="image10" alt="Graph" /></td>
<td><img src="image11" alt="Graph" /></td>
<td><img src="image12" alt="Graph" /></td>
</tr>
<tr>
<td>Seattle</td>
<td><img src="image13" alt="Graph" /></td>
<td><img src="image14" alt="Graph" /></td>
<td><img src="image15" alt="Graph" /></td>
<td><img src="image16" alt="Graph" /></td>
</tr>
<tr>
<td>Houston</td>
<td><img src="image17" alt="Graph" /></td>
<td><img src="image18" alt="Graph" /></td>
<td><img src="image19" alt="Graph" /></td>
<td><img src="image20" alt="Graph" /></td>
</tr>
<tr>
<td>Kansas</td>
<td><img src="image21" alt="Graph" /></td>
<td><img src="image22" alt="Graph" /></td>
<td><img src="image23" alt="Graph" /></td>
<td><img src="image24" alt="Graph" /></td>
</tr>
<tr>
<td>Pittsburgh</td>
<td><img src="image25" alt="Graph" /></td>
<td><img src="image26" alt="Graph" /></td>
<td><img src="image27" alt="Graph" /></td>
<td><img src="image28" alt="Graph" /></td>
</tr>
</tbody>
</table>

**Calendar Weeks**
Figure 4.C. Proportion Testing Positive for Influenza

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Nashville</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rochester</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cincinnati</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Seattle</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Houston</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kansas</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pittsburgh</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Calendar Weeks

©2021 American Academy of Pediatrics
Downloaded from www.aappublications.org/news by guest on May 30, 2021
Acute Respiratory Illnesses in Children in the SARS-CoV-2 Pandemic: Prospective Multicenter Study
Zaid Haddadin, Jennifer E. Schuster, Andrew J. Specker, Herdi Rahman, Anna Blozinski, Laura Stewart, Angela P. Campbell, Joana Y. Lively, Marian G. Michaels, John V. Williams, Julie A. Boom, Leila C. Sahni, Mary Staat, Monica McNeal, Rangaraj Selvarangan, Christopher J. Harrison, Geoffrey A. Weinberg, Peter G. Szilagyi, Janet A. Englund, Eileen J. Klein, Aaron T. Curns, Brian Rha, Gayle E. Langley, Aron J. Hall, Manish M. Patel and Natasha B. Halasa

Pediatrics originally published online May 13, 2021;

Updated Information & Services
including high resolution figures, can be found at:
http://pediatrics.aappublications.org/content/early/2021/05/11/peds.2021-051462.citation

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.aappublications.org/site/misc/Permissions.xhtml

Reprints
Information about ordering reprints can be found online:
http://www.aappublications.org/site/misc/reprints.xhtml
Acute Respiratory Illnesses in Children in the SARS-CoV-2 Pandemic: Prospective Multicenter Study
Zaid Haddadin, Jennifer E. Schuster, Andrew J. Spieker, Herdi Rahman, Anna Blozinski, Laura Stewart, Angela P. Campbell, Joana Y. Lively, Marian G. Michaels, John V. Williams, Julie A. Boom, Leila C. Sahni, Mary Staat, Monica McNeal, Rangaraj Selvarangan, Christopher J. Harrison, Geoffrey A. Weinberg, Peter G. Szilagyi, Janet A.Englund, Eileen J. Klein, Aaron T. Curns, Brian Rha, Gayle E. Langley, Aron J. Hall, Manish M. Patel and Natasha B. Halasa

Pediatrics originally published online May 13, 2021;

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://pediatrics.aappublications.org/content/early/2021/05/11/peds.2021-051462.citation